Home・Elenco Azioni・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Chiusa

12.46 -5.39

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

12.89

Massimo

13.25

Metriche Chiave
By Trading Economics
Entrata	-4.3M -18M
EPS	-0.19
Dipendenti	37
EBITDA	-5.3M -17M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+128.51% upside

Dividendi
By Acuity
Utili prossimi	3 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	86M 1.2B
Apertura precedente	17.85
Chiusura precedente	12.46

Corvus Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 set 2026, 23:56 UTC

Blackstone Inc's shares are higher in after-market hours, reflecting positive movement despite broader U.S. equity weakness. No specific news was identified to explain the rise.

14 set 2026, 23:56 UTC

RMR Group Inc shares are trading lower in after-market hours amid a broader U.S. equity decline influenced by rising crude oil prices and supply concerns.

14 set 2026, 23:56 UTC

eHealth Inc. shares are trading higher in after-market hours, recovering from earlier lows despite broader market challenges, including a lower Nasdaq close.

14 set 2026, 23:56 UTC

Geo Group Inc shares rose in after-market trading, despite broader market declines influenced by rising crude oil prices. No specific news was identified.

14 set 2026, 23:56 UTC

Extra Space Storage shares are lower in after-market hours, reflecting broader market declines amid rising crude oil prices and ongoing stock performance weakness.

14 set 2026, 23:56 UTC

CMS Energy shares are higher in after-market trading, reflecting a modest recovery from earlier fluctuations since Monday's close.

14 set 2026, 23:56 UTC

Shares of Kinder Morgan advanced slightly during after-market hours. This occurred amid a broader market recovery attempt despite lower U.S. equities.

14 set 2026, 23:56 UTC

Gentex Corp shares are higher in after-market trading, though no specific news was identified. The stock remains below its 20-day moving average.

14 set 2026, 23:56 UTC

Shares of APA Corp are higher in after-market trading, remaining stable near the upper end of their one-month range amid broader market declines.

14 set 2026, 23:56 UTC

Rogers Corp shares are higher in after-market trading, though no specific news explains the increase. Broader U.S. equities closed lower amid rising crude oil prices.

14 set 2026, 23:56 UTC

First Hawaiian Inc shares are higher in after-market trading, despite broader market volatility and major indices closing lower. No specific news was identified for the move.

14 set 2026, 23:52 UTC

Rush Enterprises shares traded lower after market hours, amid broader market concerns over rising crude oil prices and inflation ahead of the Federal Reserve meeting.

14 set 2026, 23:52 UTC

Omnicom Group Inc shares are trading lower in after-market hours amid significant weakness in the Advertising sub-sector, remaining below the 20-day moving average.

14 set 2026, 23:51 UTC

Liberty Energy Inc shares are higher in after-market trading, influenced by rising crude oil prices amid supply concerns from Saudi Arabia's pipeline shutdown.

14 set 2026, 23:51 UTC

BILL Holdings Inc shares are lower in after-market hours following a pullback from earlier gains. No specific news was identified to explain the decline.

14 set 2026, 23:51 UTC

News

Rimini Street shares lower in after-market trading despite announcing a partnership with Datacom to support Oracle and SAP software in Australia and New Zealand.

14 set 2026, 23:51 UTC

National Healthcare Corp shares are higher in after-market trading, following a series of daily gains since Monday's close. No specific news was identified.

14 set 2026, 23:51 UTC

Correlated Moves

Social Media

SLB NV shares are higher in after-market trading, reflecting strength amid rising crude oil prices and broader energy sector gains, despite mixed sentiment on social media.

14 set 2026, 23:51 UTC

Devon Energy shares are higher in after-market hours, tracking a broader oil sector trend amid rising crude prices due to supply concerns from Saudi Arabia.

14 set 2026, 23:51 UTC

China's Industrial Production YoY data set for release on September 15, 2026, with a forecasted growth of 4.8%, amid mixed market sentiment influenced by inflation and geopolitical tensions.

14 set 2026, 23:51 UTC

China's Retail Sales YoY data for August 2026 expected to rise modestly by 0.8%, amid ongoing concerns over consumer spending and weak performance in key sectors.

14 set 2026, 23:51 UTC

China's Fixed Asset Investment data release on September 15, 2026, forecasts a continued decline at -0.072%, raising concerns over economic stability amid ongoing property sector struggles.

14 set 2026, 23:51 UTC

US Initial Jobless Claims Expected at 205,000 Amid Stable Labor Market Sentiment Ahead of September 17 Release.

14 set 2026, 23:51 UTC

Correlated Moves

Quantumscape Corp shares are lower in after-market hours, breaking a recent trend of higher daily closes amid rising crude oil prices and inflationary pressures.

14 set 2026, 23:51 UTC

Park Hotels & Resorts shares are lower in after-market hours, continuing a downward trend amid rising crude oil prices and broader market pressures.

14 set 2026, 23:51 UTC

Baidu Inc. shares are higher in after-market trading, continuing a modest advance since Monday's close, despite remaining below the 20-day moving average.

14 set 2026, 23:51 UTC

Shares of Synchrony Financial are higher in after-market trading, recovering from a recent low. Broader market factors include rising crude oil prices and inflation concerns.

14 set 2026, 23:51 UTC

News

Shares of Gartner Inc are lower in after-market hours following unusual weakness, despite the recent launch of its IT Symposium/Xpo conference highlighting key technology trends.

14 set 2026, 23:51 UTC

Correlated Moves

Social Media

SentinelOne Inc is trading lower in after-market hours amid broader market weakness and fluctuating oil prices ahead of the Federal Reserve's policy meeting.

14 set 2026, 23:51 UTC

Correlated Moves

Ichor Holdings Ltd shares are higher in after-market trading, supported by a positive trend in the semiconductor sector and gains in Entegris Inc.

Confronto tra pari

Modifica del prezzo

Corvus Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

128.51% in crescita

Previsioni per 12 mesi

Media 29.5 USD 128.51%

Alto 33 USD

Basso 27 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Corvus Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a Corvus Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.